Adipokine update - New molecules, new functions;Adipokine update - Neue moleküle, neue funktionen

Wiener Medizinische Wochenschrift

Volumn 160, Issue 15-16, 2010, Pages 377-390

  Gelsinger, Carmen ^a   Tschoner, Alexander ^a   Kaser, Susanne ^a   Ebenbichler, Christoph F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adipokines; Diabetes; Inflammatory disease; Insulin resistance; Metabolic syndrome; Obesity; Visceral adipose tissue

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPSIN; APELIN; FATTY ACID BINDING PROTEIN 4; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ENDOCRINE GLAND; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MEDICAL RESEARCH; METABOLIC SYNDROME X; MOLECULE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SUBCUTANEOUS FAT;

ADIPOCYTES; ADIPOKINES; ADIPONECTIN; ANIMALS; ATHEROSCLEROSIS; BRAIN; CARDIOVASCULAR DISEASES; CHEMOKINES; COMPLEMENT FACTOR D; CYTOKINES; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS; MALE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; RECEPTORS, ADIPOKINE; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; SERPINS;

EID: 78149293294     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0781-6     Document Type: Review

References (184)

1. Kopelman PG. Obesity as a medical problem. Nature, 404:635-643, 2000.
2. Aggoun Y. Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res, 61:653-659, 2007.
3. Daniels SR, Jacobson MS, McCrindle BW, et al. American Heart Association Childhood Obesity Research Summit: executive summary. Circulation, 119:2114-2123, 2009.
4. Eckel RH, York DA, Rossner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation, 110:2968-2975, 2004.
5. Fobi MA. Surgical treatment of obesity: a review. J Natl Med Assoc, 96:61-75, 2004.
6. Meyers MR, Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes, 14:365-369, 2007.
7. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med, 55:33-50, 1961.
8. Gill T, Chittleborough C, Taylor A, et al. Body mass index, waist hip ratio, and waist circumference: which measure to classify obesity? Soz Praventivmed, 48:191-200, 2003.
9. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis, 10:493-496, 1990. (Pubitemid 20220571)
10. Sparrow D, Borkan GA, Gerzof SG, et al. Relationship of fat distribution to glucose tolerance. Results of computed tomography in male participants of the Normative Aging Study. Diabetes, 35:411-415, 1986.
11. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism, 36:54-59, 1987.
12. Seidell JC, Bjorntorp P, Sjostrom L, et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism, 39:897-901, 1990.
13. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care, 14:1132-1143, 1991.
14. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett, 580:2917-2921, 2006.
15. Tarquini R, Lazzeri C, Laffi G, et al. Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med, 2:165-176, 2007.
16. MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab, 6:159-161, 2007.
17. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond), 114:275-288, 2008.
18. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 112:1821-1830, 2003.
19. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest, 112:1796-1808, 2003.
20. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm, 74:443-477, 2006.
21. Toborek M, Kaiser S. Endothelial cell functions. Relationship to atherogenesis. Basic Res Cardiol, 94:295-314, 1999.
22. Szmitko PE, Teoh H, Stewart DJ, et al. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, 292: H1655-H1663, 2007.
23. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-126, 1999.
24. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes, 54:2305-2313, 2005.
25. Rasouli N, Molavi B, Elbein SC, et al. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab, 9:1-10, 2007.
26. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 89:2548-2556, 2004.
27. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med, 321:337-343, 1989.
28. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14:173-194, 1991.
29. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 259:87-91, 1993.
30. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 95:2409-2415, 1995.
31. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest, 115:1111-1119, 2005.
32. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem, 282:28175-28188, 2007.
33. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun, 221:286-289, 1996.
34. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 270:26746-26749, 1995.
35. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem, 271:10697-10703, 1996.
36. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem, 120:803-812, 1996.
37. Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest, 67:449-458, 2007.
38. Pineiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett, 579:5163-5169, 2005.
39. Delaigle AM, Jonas JC, Bauche IB, et al. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology, 145:5589-5597, 2004.
40. Wolf AM, Wolf D, Avila MA, et al. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol, 44:537-543, 2006.
41. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone, 35:842-849, 2004.
42. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA, 98:2005-2010, 2001.
43. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem, 278:9073-9085, 2003.
44. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem, 278:40352-40363, 2003.
45. Wang Y, Lam KS, Chan L, et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem, 281:16391-16400, 2006.
46. Neumeier M, Weigert J, Schaffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol, 79:803-808, 2006.
47. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA, 101:10308-10313, 2004.
48. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423:762-769, 2003.
49. Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun, 312:1118-1122, 2003.
50. Tsuchida A, Yamauchi T, Ito Y, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem, 279:30817-30822, 2004.
51. Rasmussen MS, Lihn AS, Pedersen SB, et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring), 14:28-35, 2006.
52. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab, 285: E527-E533, 2003.
53. Fasshauer M, Klein J, Neumann S, et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett, 507:142-146, 2001.
54. Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 290:1084-1089, 2002.
55. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia, 46:1594-1603, 2003.
56. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr, 23:963-974, 2004.
57. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun, 323:630-635, 2004.
58. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 8:1288-1295, 2002.
59. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA, 99:16309-16313, 2002.
60. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab, 13:84-89, 2002.
61. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 7:941-946, 2001.
62. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adiposetissue in lean and obese subjects. Mol Cell Endocrinol, 219:9-15, 2004.
63. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest, 108:1875-1881, 2001.
64. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 7:947-953, 2001.
65. Chinetti G, Zawadski C, Fruchart JC, et al. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun, 314:151-158, 2004.
66. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab, 89:765-769, 2004.
67. Fargnoli J, Sun Q, Olenczuk D, et al. Resistin is associated with biomarkers of inflammation while total and HMW adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol, 162:281-288, 2010.
68. Engl J, Sturm W, Sandhofer A, et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest, 38:238-244, 2008.
69. Engl J, Bobbert T, Ciardi C, et al. Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity (Silver Spring), 15:1172-1178, 2007.
70. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med, 14:741-751, 2008.
71. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol, 115:911-919, 2005.
72. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med, 82:4-11, 2004.
73. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 372:425-432, 1994.
74. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 269:543-546, 1995.
75. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science, 269:540-543, 1995.
76. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell, 83:1263-1271, 1995.
77. Tartaglia LA. The leptin receptor. J Biol Chem, 272:6093-6096, 1997.
78. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol, 70:537-556, 2008.
79. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab, 93: S64-S73, 2008.
80. Buettner C, Pocai A, Muse ED, et al. Critical role of STAT3 in leptin's metabolic actions. Cell Metab, 4:49-60, 2006.
81. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med, 14:667-675, 2008.
82. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature, 404:661-671, 2000.
83. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology, 138:4489-4492, 1997.
84. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature, 411:480-484, 2001.
85. Zhang W, Della-Fera MA, Hartzell DL, et al. Adipose tissue gene expression profiles in ob/ob mice treated with leptin. Life Sci, 83:35-42, 2008.
86. Fantuzzi G. Three questions about leptin and immunity. Brain Behav Immun, 23 (4):405-410, 2008.
87. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol, 133:11-19, 2003.
88. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol, 4:1-13, 2007.
89. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res, 16:1426-1433, 2001.
90. Reseland JE, Gordeladze JO. Role of leptin in bone growth: central player or peripheral supporter? FEBS Lett, 528:40-42, 2002.
91. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell, 100:197-207, 2000.
92. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell, 111:305-317, 2002.
93. Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer, 123:2543-2556, 2008.
94. Ratke J, Entschladen F, Niggemann B, et al. Leptin stimulates the migration of colon carcinoma cells by multiple signalling pathways. Endocr Relat Cancer, 17 (1):179-189, 2010.
95. Frankenberry KA, Skinner H, Somasundar P, et al. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol, 28:985-993, 2006.
96. Somasundar P, Frankenberry KA, Skinner H, et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res, 118:71-82, 2004.
97. Lang K, Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal, 7:27, 2009.
98. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci, 54:1847-1856, 2009.
99. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology, 148:4687-4694, 2007.
100. Roh SG, Song SH, Choi KC, et al. Chemerin - a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun, 362:1013-1018, 2007.
101. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med, 205:2187-2190, 2008.
102. Methner A, Hermey G, Schinke B, et al. A novel G protein-coupled receptor with homology to neuropeptide and chemoattractant receptors expressed during bone development. Biochem Biophys Res Commun, 233:336-342, 1997.
103. Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med, 205:2207-2220, 2008.
104. Cash JL, Hart R, Russ A, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med, 205:767-775, 2008.
105. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cellsbychemerin, anovel processed ligand from human inflammatory fluids. J Exp Med, 198:977-985, 2003.
106. Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett, 582:573-578, 2008.
107. Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest, 2010 (in press).
108. Sommer G, Garten A, Petzold S, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond), 115:13-23, 2008.
109. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307:426-430, 2005. (Pubitemid 40139988)
110. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem, 15:1851-1862, 2008.
111. Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. Science, 307:366-367, 2005.
112. Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science, 318:565, 2007.
113. Ciardi C, Tatarczyk T, Tschoner A, et al. Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin. Nutr Metab Cardiovasc Dis, 2009 (Epub ahed of print).
114. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab, 6:363-375, 2007.
115. Wang T, Zhang X, Bheda P, et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol, 13:661-662, 2006.
116. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 178:1748-1758, 2007.
117. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 54:2911-2916, 2005.
118. Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf), 71 (2):202-207, 2008.
119. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 115:972-980, 2007.
120. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism, 56:451-458, 2007.
121. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA, 102:10610-10615, 2005.
122. Li Q, Chen R, Moriya J, et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res, 36:625-629, 2008.
123. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 57:372-377, 2008.
124. Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis, 204 (1):262-266, 2008.
125. Kloting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun, 339:430-436, 2006.
126. Lee MK, Jekal Y, Im JA, et al. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta, 411 (5-6): 381-385, 2010.
127. Patel SD, Rajala MW, Rossetti L, et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science, 304:1154-1158, 2004.
128. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 409:307-312, 2001.
129. Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissuespecific secretory factor inhibits adipocyte differentiation. J Biol Chem, 276:11252-11256, 2001.
130. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J, 19:4046-4055, 2000.
131. Graveleau C, Zaha VG, Mohajer A, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem, 280:31679-31685, 2005.
132. Rangwala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 53:1937-1941, 2004.
133. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science, 303:1195-1198, 2004.
134. Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med, 81:218-226, 2003.
135. Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 53:1671-1679, 2004.
136. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor gamma agonists. J Biol Chem, 276:25651-25653, 2001.
137. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab, 88:5452-5455, 2003.
138. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptorgamma action in humans. Diabetes, 50:2199-2202, 2001.
139. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun, 285:561-564, 2001.
140. McTernan CL, McTernan PG, Harte AL, et al. Resistin, central obesity, and type 2 diabetes. Lancet, 359:46-47, 2002.
141. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab, 87:2407, 2002.
142. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab, 93:3165-3172, 2008.
143. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab, 88:6098-6106, 2003.
144. Kaser S, Kaser A, Sandhofer A, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun, 309:286-290, 2003.
145. Fasshauer M, Klein J, Neumann S, et al. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 288:1027-1031, 2001.
146. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56:1655-1661, 2007.
147. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab, 290: E1253-E1261, 2006.
148. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci, 27:190-194, 2006.
149. Higuchi K, Masaki T, Gotoh K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology, 148:2690-2697, 2007.
150. Yue P, Jin H, Aillaud-Manzanera M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab (Epub ahead of print), 2009.
151. Grisk O. Apelin and vascular dysfunction in type 2 diabetes. Cardiovasc Res, 74:339-340, 2007.
152. Zeng XJ, Zhang LK, Wang HX, et al. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides, 30:1144-1152, 2009.
153. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem, 267:9210-9213, 1992.
154. Gabrielsson BG, Johansson JM, Lonn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res, 11:699-708, 2003.
155. Quadro L, Blaner WS, Salchow DJ, et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. Embo J, 18:4633-4644, 1999.
156. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature, 409:729-733, 2001.
157. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436:356-362, 2005.
158. Basualdo CG, Wein EE, Basu TK. Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. J Am Coll Nutr, 16:39-45, 1997.
159. Abahusain MA, Wright J, Dickerson JW, et al. Retinol, alphatocopherol and carotenoids in diabetes. Eur J Clin Nutr, 53:630-635, 1999.
160. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med, 354:2552-2563, 2006.
161. Gavi S, Qurashi S, Melendez MM, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes: response to Cho et al. Diabetes Care, 30: e7, 2007; author reply e8.
162. Bobbert P, Weithauser A, Andres J, et al. Increased plasma retinol binding protein 4 levels in patients with inflammatory cardiomyopathy. Eur J Heart Fail, 11:1163-1168, 2009.
163. Yao-Borengasser A, Varma V, Bodles AM, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab, 92:2590-2597, 2007.
164. Tschoner A, Sturm W, Engl J, et al. Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss. Obesity (Silver Spring), 16:2439-2444, 2008.
165. Haider DG, Schindler K, Prager G, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab, 92:1168-1171, 2007.
166. Lim S, Choi SH, Jeong IK, et al. Insulin-sensitizing effects of exercise on adiponectin and retinol-binding protein-4 concentrations in young and middle-aged women. J Clin Endocrinol Metab, 93:2263-2268, 2008.
167. Balagopal P, Graham TE, Kahn BB, et al. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab, 92:1971-1974, 2007.
168. Ingelsson E, Sundstrom J, Melhus H, et al. Circulating retinolbinding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis, 206:239-244, 2009.
169. Makowski L, Hotamisligil GS. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr, 134:2464S-2468S, 2004.
170. Furuhashi M, Tuncman G, Gorgun CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 447:959-965, 2007.
171. Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acidbinding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA, 103:6970-6975, 2006.
172. Rhee EJ, Lee WY, Park CY, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol, 160 (2):165-172, 2008.
173. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem, 52:405-413, 2006.
174. Engl J, Ciardi C, Tatarczyk T, et al. A-FABP - a biomarker associated with the metabolic syndrome and/or an indicator of weight change? Obesity (Silver Spring), 16:1838-1842, 2008.
175. Engl J, Tschoner A, Willis M, et al. Adipocyte fatty acid binding protein during refeeding of female patients with anorexia nervosa. Eur J Nutr, 48:403-408, 2009.
176. Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care, 30:2667-2672, 2007.
177. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation, 115:1537-1543, 2007.
178. Hancke K, Grubeck D, Hauser N, et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat, 119 (2):367, 2010.
179. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch, 452:418-427, 2006.
180. Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res, 39:250-255, 2007.
181. Mateo T, Naim Abu Nabah Y, Losada M, et al. A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II- stimulated arterioles. Blood, 110:1895-1902, 2007.
182. Hivert MF, Sullivan LM, Shrader P, et al. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. Metabolism, 59 (4):540-546, 2010.
183. Ogawa W, Kasuga M. Cell signaling. Fat stress and liver resistance. Science, 322:1483-1484, 2008.
184. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol, 27:2250-2257, 2007.